Factors Associated With Willingness to Receive a COVID-19 Vaccine Among 23,819 Adults Aged 50 Years or Older: An Analysis of the Canadian Longitudinal Study on Aging.
COVID-19
Canada
Canadian Longitudinal Study on Aging
SARS-CoV-2
adults
coronavirus disease 2019
vaccination
vaccines
Journal
American journal of epidemiology
ISSN: 1476-6256
Titre abrégé: Am J Epidemiol
Pays: United States
ID NLM: 7910653
Informations de publication
Date de publication:
20 05 2022
20 05 2022
Historique:
received:
23
05
2021
revised:
01
02
2022
accepted:
03
02
2022
pubmed:
16
2
2022
medline:
9
6
2022
entrez:
15
2
2022
Statut:
ppublish
Résumé
Identifying persons who are least willing to receive a coronavirus disease 2019 (COVID-19) vaccine is critical for increasing uptake via targeted outreach. We conducted a survey of 23,819 Canadian Longitudinal Study on Aging participants from September 29 to December 29, 2020, to assess factors associated with COVID-19 vaccination willingness and reasons for willingness or lack thereof. Among adults aged 50-96 years, 84.1% (95% confidence interval (CI): 83.7, 84.6) were very or somewhat willing to receive a COVID-19 vaccine; 15.9% (95% CI: 15.4, 16.3) were uncertain or very or somewhat unwilling. Based on logistic regression, those who were younger, female, had lower education and income, were non-White, and lived in a rural area were less willing to receive a COVID-19 vaccine. After controlling for these factors, recent receipt of influenza vaccine (adjusted odds ratio = 14.3, 95% CI: 12.5, 16.2) or planning to receive influenza vaccine (adjusted odds ratio = 10.5, 95% CI: 9.5, 11.6), as compared with no receipt or planning, was most strongly associated with COVID-19 vaccination willingness. Willingness was also associated with believing one had never been infected with severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) and experiencing negative pandemic consequences. Safety concerns were most common among those unwilling. Our comprehensive assessment of COVID-19 vaccination willingness among older adults in Canada, a prioritized group for vaccination due to their risk of severe COVID-19 outcomes, provides a road map for conducting outreach to increase uptake, which is urgently needed.
Identifiants
pubmed: 35166332
pii: 6528789
doi: 10.1093/aje/kwac029
pmc: PMC8903402
doi:
Substances chimiques
COVID-19 Vaccines
0
Influenza Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
987-998Subventions
Organisme : CIHR
Pays : Canada
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health.
Références
Proc Natl Acad Sci U S A. 2021 Mar 16;118(11):
pubmed: 33632802
Nat Med. 2021 Feb;27(2):225-228
pubmed: 33082575
Can J Aging. 2015 Sep;34(3):366-77
pubmed: 26300192
Proc Natl Acad Sci U S A. 2021 Apr 13;118(15):
pubmed: 33731429
Lancet. 2021 Mar 13;397(10278):1023-1034
pubmed: 33587887
Can Commun Dis Rep. 2016 Dec 01;42(12):246-251
pubmed: 29769995
Eur J Epidemiol. 2020 Dec;35(12):1123-1138
pubmed: 33289900
Vaccine. 2014 Apr 1;32(16):1841-7
pubmed: 24530926
PLoS One. 2021 May 24;16(5):e0251963
pubmed: 34029345
BMC Infect Dis. 2021 Apr 12;21(1):338
pubmed: 33845781
Int J Epidemiol. 2019 Dec 1;48(6):1752-1753j
pubmed: 31633757
Clin Neuropsychol. 2017 Jan;31(1):233-250
pubmed: 27830627
BMC Public Health. 2019 Feb 28;19(1):243
pubmed: 30819126
Vaccine. 2018 Jun 27;36(28):4118-4125
pubmed: 29789242